Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

66.7%

4 terminated/withdrawn out of 6 trials

Success Rate

33.3%

-53.2% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2

5(83.3%)

Phase 1

1(16.7%)

6Total

Phase 2(5)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT00742612Phase 2Terminated

Effect of ARC1779 on Cerebral Microembolism in Patients Undergoing Carotid Endarterectomy

Role: lead

NCT00726544Phase 2Terminated

Clinical Outcome Study of ARC1779 Injection in Patients With Thrombotic Microangiopathy

Role: lead

NCT00694785Phase 2Withdrawn

A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of ARC1779 Injection in Patients With Von Willebrand Disease Type 2B

Role: lead

NCT00507338Phase 2Terminated

Study of ARC1779 in Patients With Acute Myocardial Infarction Undergoing PCI

Role: lead

NCT00632242Phase 2Completed

ARC1779 Injection in Patients With Von Willebrand Factor-Related Platelet Function Disorders

Role: lead

NCT00432770Phase 1Completed

Safety, Pharmacokinetics, and Pharmacodynamics of ARC1779 in Healthy Volunteers

Role: lead

All 6 trials loaded